Trial Profile
Allogeneic Transplantation Using Venetoclax, Timed Sequential Busulfan,Cladribine, and Fludarabine Conditioning in Patients With AML and MDS
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Cladribine (Primary) ; Fludarabine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 11 Sep 2023 Planned End Date changed from 31 Oct 2023 to 31 Oct 2025.
- 11 Sep 2023 Planned primary completion date changed from 31 Oct 2023 to 31 Oct 2025.
- 15 Jun 2023 Results reporting safety and efficacy data presented at the 28th Congress of the European Haematology Association